Randomized controlled trial shows 67% increase in adherence in patients with ischemic stroke

Data Presented Today at Connected Health Symposium Highlight Suboptimal and Undetected Nonadherence in Patients Diagnosed with Ischemic Stroke

New York, Oct. 27, 2016 — AiCure, a clinically-validated artificial intelligence company that visually confirms medication ingestion on smartphones, announced that study results presented today during the Connected Health Symposium validate that use of the AiCure Platform can significantly increase adherence and help to immediately detect nonadherence in patients taking direct oral anticoagulants (DOACs), for whom no regulator monitoring is required but where adherence is a significant concern.

Eligible patients diagnosed with ischemic stroke (with or without preceding transient ischemic attack and with a score between 1 and 20 on the NIH Stroke Scale [NIHSS]) and receiving oral anticoagulation therapy, were randomized to daily monitoring by the AI Platform (intervention) or to no daily monitoring (control) in this 12-week, randomized, parallel-group, controlled, single-site study. All patients were prescribed warfarin, dabigatran, rivaroxaban, or apixaban. Medication adherence was measured by pill counts, plasma sampling, and the AiCure Platform.

Results: Mean (SD) cumulative adherence (visual confirmation of drug administration) was 90.5% (7.5%). A total of 108 plasma samples were collected across both groups. Plasma samples were marked as adherent if drug concentration levels were above the minimum required therapeutic range (cMin). Fifty percent and 100% of patients (DOACs and warfarin) in the control and intervention groups, respectively, had all samples above cMin. Among patients deemed nonadherent, all were in the control group and all were prescribed DOACs. At all clinic visits, patients in the intervention group had higher standardized plasma drug concentrations than patients in the control group.

“Average adherence in patients with chronic conditions is 50%. Being able to demonstrate an absolute improvement of 67% in patients taking DOACs and monitored by the AiCure Platform – and confirmed by drug levels – demonstrates the potential value of daily real-time monitoring to measure and maximize adherence. Few studies have deployed smartphone apps in middle-aged or elderly populations”, said Adam Hanina, CEO of AiCure. “Artificial Intelligence platforms have the potential to accurately monitor medication ingestion and change patient behavior.”